Introduction
Paraneoplastic syndromes are a group of rare disorders with a wide range of physical symptoms, which are brought about by the indirect action of malignancy. The mechanism behind this is thought to be due to antibodies expressed against neuronal proteins produced by the tumour. 1 Anti-Hu paraneoplastic (AHP) encephalitis is one of these syndromes associated with predominantly neurological signs and symptoms. Hu antigens, expressed by a tumour, trigger a humoural and cell-mediated response which cross-reacts with normal neural tissue. The treatment for paraneoplastic syndromes usually includes a dampening of the immune response as well as direct treatment of the tumour. The neoplasm is frequently not isolated until after the onset of symptoms if at all and the outcome of these patients is often poor. 1, 2 However in this case report, we present a patient who despite requiring intubation and ventilation, responded well to corticosteroids and was discharged from hospital. The associated malignancy was identified by PET-CT, was chemotherapy-sensitive and significantly reduced in size.
Case report
A 60-year-old female ex-smoker with a background of hypercholesterolaemia but no other significant past medical history presented to the emergency department with neurological symptoms of one month duration. These progressive symptoms included a salty taste in the mouth, leftsided inattention, dizziness, dyspraxia and slurring of speech. On examination she had some mild bibasal crackles, an ataxic gait but otherwise no focal neurology and blood tests were all within normal reference ranges. The plain chest X-ray showed clear lung fields and she had a non-contrast-enhanced CT (computed tomography) head scan which showed no acute changes. A subsequent diffusion-weighted MRI (magnetic resonance imaging) head scan demonstrated 'tiny foci white matter changes most likely to represent ischaemic gliosis but otherwise within normal limits.' The patient was thought to have had a cerebrovascular event and was discharged home with physiotherapy and a follow-up appointment in six weeks.
In the first four weeks following discharge she was stable; however, her symptoms worsened in the following fortnight and she re-presented to the emergency department. Her dizziness had progressed to the extent that she could no longer mobilise. During this admission, it was thought that she was Hallpike test positive, but she was also noted to have a significant postural drop in her blood pressure (supine 124/79, standing 72/59). A Synacthen test was performed, eliciting a normal response (689 nmol pre-ACTH [adrenocorticotropic hormone], 1,411 nmol post-ACTH). The orthostatic hypotension was refractory to a combination of midodrine and fludrocortisone. She fell twice during her admission and developed diplopia on left lateral gaze and upward nystagmus.
During this admission her clinical signs continued to progress and her oxyhaemoglobin saturation fell, needing highflow oxygen (SpO 2 92% on 15 L flow); arterial blood gases (ABGs) demonstrated type II respiratory failure (pH 7.37, pCO 2 8.0 kPa, pO 2 9.1 kPa, lactate 0.5 mmol/L). There was no clinical evidence of sepsis and blood tests were unremarkable so there was concern about the possibility of a pulmonary embolus, but a CTPA (computed tomography pulmonary angiogram) proved negative. A neurological review queried myasthenia as a cause, and pyridostigmine was trialled but this did not provide any benefit. She had serial spirometry which showed falling forced vital capacities (1.2 L initially then 0.87 L) and it was during this time that it was first noticed that her respiratory rate was 6/minute when asleep but rose when she became alert. A review by the intensive care department suggested a trial of noninvasive ventilation (NIV) on the wards. Further neurological review queried a paraneoplastic brainstem encephalopathy, and an autoantibody screen was requested. Despite NIV pressures of 18/4 she became acidaemic and was transferred to the ICU for further NIV and close observation; while there she became apnoeic and was intubated without the need for sedation or muscle relaxants. She tolerated the endotracheal tube despite being alert, (Glasgow Coma Score [GCS]: E -4, M -6, Vendotracheal tube sited). A lumbar puncture was normal (white cell count 4, red cell count 12, protein 4.6, glucose 5.2, no growth) with the exception of the detection of oligoclonal bands. She was started on high doses of methylprednisolone
Ondine's curse: a case of anti-Hu paraneoplastic syndrome 3C00

C Brookes, R McIntosh, S Twigg
A 60-year-old patient presented with neurological symptoms which proved to be a paraneoplastic syndrome secondary to a small-cell lung cancer. The investigations and treatment for these syndromes are discussed. The patient improved with high dose steroids and chemotherapy.
Keywords: Hu paraneoplastic encephalomyelitis antigens; paraneoplastic syndromes nervous system/physiopathology
Case reports
(3 x 1 g) and regular prednisolone (80 mg daily). This brought about a marked improvement in her symptoms, with eye movements showing the first signs of recovery and although she still had long apnoeic episodes while intubated, particularly while sleeping; these became less frequent with time.
After four days a tracheostomy was sited and a prolonged wean from the ventilator began, complicated by a ventilatoracquired pneumonia requiring IV antibiotics, but one month after her admission she was decannulated. During this period her blood results showed that she was anti-Hu antibody positive, confirming a paraneoplastic syndrome, but the search for a neoplasm was initially fruitless, with CT chest/abdomen/ pelvis showing no positive findings and a breast examination being normal (an ultrasound scan of the abdomen had earlier shown no findings suspicious for ovarian cancer). Thirty days after admission to ICU she was discharged to the ward; there she had a mammogram, which was normal, followed by a whole body PET-CT (positron emission tomography) scan. This was the first imaging technique to reveal a suspicious lesion, showing a number of cavitating lesions of probable inflammatory origin, but more importantly an isolated, nodal mass which showed intense fludeoxyglucose (FDG) activity in the subcarinal region. This was amenable to biopsy through endobronchial ultrasound (EBUS) and the histological findings were consistent with small cell lung carcinoma (SCLC).
The patient was discharged from hospital nearly three months after admission on a reducing regime of steroids and after starting a course of chemotherapy. At the time of writing, she is being regularly reviewed in neurology and respiratory outpatient clinics and continues to improve. The remnant features of her life-threatening condition are difficulty mobilising, the need for a wheelchair and some upbeat nystagmus on superior gaze. Her SCLC is responsive to chemotherapy and follow-up CT imaging shows marked improvements by comparison with her PET-CT; the cavitating lesions have resolved and the subcarinal lymphadenopathy has significantly reduced in size from 2.5 cm in diameter to 6 x 19 mm.
Discussion
Ondine' s curse is a folk tale which features in French and German mythology. It describes a beautiful nymph called Ondine who, as a result of bearing a human child, lost her youthfulness and good looks. Ondine' s husband, Palemon, became disinterested in her and committed adultery; Ondine discovered Palemon' s treachery and cursed him that if he ever fell asleep he would stop breathing, so he had to remain awake to stay alive. The paraneoplastic syndrome that we have described is effectively a medical case of Ondine' s curse. 3 Paraneoplastic syndromes have been recognised for more than forty years. 4 The anti-Hu antibodies were first described in 1985. 5 Anti-Hu encephalomyelitis can present in a variety of ways; a large case series reviewing 200 patients showed that dysfunction was confined to one area of the nervous system in 30%, with sensory neuropathy the most common feature (54%). In descending order of prevalence the other anti-Hu manifestations include cerebellar, cortical, brainstem, sensorimotor and autonomic syndromes. In this case series, 11% of patients exhibited a multifocal syndrome and the patient we describe would be in this category. This study also highlighted that only in 75% of these patients was a malignancy identified, with SCLC by far the most common neoplasm. 6 Our patient exhibited central hypoventilation as her condition progressed, resulting in the loss of involuntary respiratory drive and consequent apnoea while asleep. Her voluntary respiratory drive was preserved. This has also been seen in other cases and one report describes three patients who had central hypoventilation as their presenting symptom. 7 The good clinical outcome in this case is relatively unusual by comparison with other AHP cases reported in the literature. In one case series, which described 22 patients with AHP brainstem encephalitis, all but one of the patients were either dead or ventilator-dependent at five months (the other patient was still alive nine years later with no malignancy identified). 2 In our case, the patient is still alive and both clinically and radiologically improving eight months post presentation.
The poor prognosis of these conditions is partly explained by the fact that they are often refractory to treatment. However, a second possible explanation is that they present diagnostic challenges and the condition is sometimes only confirmed very late in the course of the disease. This is particularly true for brainstem manifestations of paraneoplastic syndromes. These are considered 'non-classical' syndromes and are more likely to be caused by non-neoplastic disease. Non-neoplastic differentials should be investigated but if a paraneoplastic syndrome is not part of the differential diagnosis, diagnosis and treatment may be delayed leading to adverse outcomes.
To help establish a diagnosis, a set of criteria was recommended in 2004. These criteria included: whether or not the paraneoplastic syndrome present was classical or nonclassical, whether tumour was absent or present and whether onconeural antibodies were identified or not. This is presented as a flow diagram (see Figure 1 ) and the route through the flow diagram for this case is highlighted.
Once a diagnosis of paraneoplastic syndrome is confirmed, screening for the tumour should commence. Earlier imaging will likely lead to earlier diagnosis, treatment and better clinical outcomes. In each case of paraneoplastic syndrome there will be a particular type of malignancy suspected and the literature suggests specific imaging modalities on this basis. In AHP syndrome around 90% of cases are secondary to SCLC. The recommended primary imaging technique is thoracic CT, which is 80-85% sensitive. If this is negative, the next imaging modality is FDG-PET or FDG-PET/CT and the third-line recommended diagnostic technique is bronchoscopy/EBUS. In the case we present, thoracic CT did not reveal the SCLC but it was seen on FDG-PET/CT scan and histological diagnosis was made on EBUS. 9 Treatment options for paraneoplastic neurological syndromes include direct tumour therapy and immunosuppression. Directly targeting the tumour has been shown in case series to have beneficial effects; treated anti-Hu paraneoplastic encephalomyelitis was linked with recovery or stability of symptoms with an odds ratio of 4.56. 10, 11 It has been demonstrated that patients with cerebellar degeneration and onconeural antibodies live significantly longer if their tumour is treated. 12 There is no evidence to suggest that tumour therapy should differ if it presents with a paraneoplastic syndrome; treatment should be based upon usual oncological guidance.
There are currently no studies on the optimal type of immunosuppression but first-line options include corticosteroids, plasmapheresis (which however does not directly target cell-mediated autoimmune processes), IV immunoglobulins or immunoadsorption. Immunosuppressive therapy is not supported by good quality evidence in the literature. 13, 14 In the present case however, there was demonstrable improvement in the patient' s signs and symptoms.
Conclusion
This case of AHP encephalitis is unusual in having a good outcome following treatment with high-dose corticosteroids and chemotherapy for SCLC. It therefore confirms the importance of attempting treatment with these medications and highlights the value of early imaging and different imaging modalities.
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